Brookdale Senior Living (BKD) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Achieved 80 basis points sequential and 130 basis points year-over-year occupancy growth, outperforming industry averages despite continued weakness in paid third-party referral sources.
Generated $14 million of adjusted free cash flow and $92.2 million adjusted EBITDA in Q3 2024, a 15% year-over-year increase, driven by higher occupancy and rates.
Expanded HealthPlus program to over 130 communities, with third-party validation of superior clinical outcomes.
Completed or entered agreements to acquire 41 leased communities for $610 million, funded by convertible notes, agency debt, and cash, with closings expected by year-end.
Named to Newsweek's Most Loved Workplaces list.
Financial highlights
Q3 2024 revenue grew 3.7% year-over-year to $784.2 million, with resident fees up 3.7% and facility operating expenses up 2.0%.
Consolidated RevPAR increased 5.9% year-over-year to $4,869; same community RevPAR up 5.6%.
Adjusted EBITDA margin and operating income margin improved year-over-year; same community adjusted operating income margin expanded by 100-140 basis points.
Net loss for Q3 2024 was $50.7 million, unchanged from Q3 2023.
Total liquidity at September 30, 2024, was $324.1 million, including $254.7 million in cash and $29.7 million in marketable securities.
Outlook and guidance
Q4 2024 guidance: RevPAR growth of 5.0%-5.5% year-over-year and adjusted EBITDA of $93-$98 million.
Expect sequential occupancy increase in Q4 and continued year-over-year growth in occupancy and adjusted EBITDA.
Guidance includes $3 million in hurricane-related expenses and lower utilities expense as peak season ends.
2025 expected to deliver steady occupancy and adjusted EBITDA growth, and meaningful free cash flow improvement.
Full-year 2024 non-development capital expenditures projected at approximately $180 million.
Latest events from Brookdale Senior Living
- Operational focus, targeted CapEx, and market-driven M&A support growth amid strong demand.BKD
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Record 2025 EBITDA and occupancy set stage for robust 2026 growth and portfolio streamlining.BKD
Q4 202519 Feb 2026 - Q2 saw 20% Adjusted EBITDA growth, higher occupancy, but a wider net loss on higher costs.BKD
Q2 20241 Feb 2026 - 2026 targets $502–$516M Adjusted EBITDA and 8–9% RevPAR growth, led by operational transformation.BKD
Investor Day 202630 Jan 2026 - Strategic acquisitions, strong occupancy, and HealthPlus expansion drive positive 2025 outlook.BKD
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Accelerating occupancy, strong cash flow, and innovation position for sustained growth.BKD
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - 2024 results beat guidance; 2025 targets 11%-15% EBITDA growth and positive cash flow.BKD
Q4 202415 Dec 2025 - Contested director election, performance-based pay, and auditor ratification headline the 2025 proxy.BKD
Proxy Filing1 Dec 2025 - Ortelius seeks to overhaul board leadership to address underperformance and drive value creation.BKD
Proxy Filing1 Dec 2025